Veracyte
New publications have expanded the discussion around the Envisia lung disease test as the firm builds evidence for its recently launched lung cancer nasal swab assay.Â
Veracyte Q1 Revenues Jump 85 Percent
Test revenues grew about 69 percent, driven by the firm's Decipher urology portfolio, while product revenues dropped slightly, facing currency headwinds.
Veracyte Revenues Almost Double in Q4
The company saw significant gains in both its lab testing and biopharmaceutical revenues, with more incremental growth in product sales.
In Brief This Week: Roche, Veracyte, Hologic, Danaher, Chembio Diagnostics, Natera, and More
News items for the in vitro diagnostics industry for the week of Nov. 29, 2021.
Veracyte Q3 Revenues Nearly Double
Total revenues grew to $60.4 million and testing volume for its genomic tests were up 79 percent year over year.
Oct 28, 2021
Jun 4, 2021
Jun 1, 2021
Veracyte to Acquire HalioDx for €260M
Feb 17, 2021